Association of FOSB exon 4 unmethylation with poor prognosis in patients with late‑stage non‑small cell lung cancer

Kim,Dong Sun; Lee,Won Kee; Park,Jae Yong

doi:10.3892/or.2019.7431

Association of FOSB exon 4 unmethylation with poor prognosis in patients with late‑stage non‑small cell lung cancer

Authors:
- Dong Sun Kim
- Won Kee Lee
- Jae Yong Park
View Affiliations

Affiliations: Department of Anatomy and BK21 Plus KNU Biomedical Convergence Program, School of Medicine, Kyungpook National University, Daegu 702‑422, Republic of Korea, Department of Preventive Medicine, School of Medicine, Kyungpook National University, Daegu 702‑422, Republic of Korea, Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu 702‑422, Republic of Korea
Published online on: December 13, 2019 https://doi.org/10.3892/or.2019.7431
Pages: 655-661

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Alterations in DNA methylation have a central role in the development and outcome of most human malignancies. Non‑small cell lung cancer (NSCLC), the most common lung cancer, leads to the largest number of cancer‑related deaths worldwide. FBJ murine osteosarcoma viral oncogene homolog B (FOSB) is a key component of the activator protein‑1 transcription factor and regulates gene networks associated within oncogenic transformation. The role of FOSB in the development of NSCLC is still elusive. Therefore, the methylation status of the FOSB gene was investigated in NSCLC and its clinical significance in NSCLC progression was evaluated. The methylation status of the promoter and exon 4 regions of the FOSB gene were analyzed in 176 NSCLC specimens by bisulfite pyrosequencing and the association between FOSB methylation status and patient survival was investigated. Compared to adjacent non‑malignant tissues, FOSB promoter exhibited exclusive unmethylation in all malignant tissues and the exon 4 region was found unmethylated in 18 (10.2% of the total) tumor samples. Exon 4 unmethylation was associated with downregulation of its mRNA and tended to occur in patients with lymph node metastasis. Univariate and multivariate analyses revealed that exon 4 unmethylation was significantly associated with unfavorable overall survival in patients with stage II‑IIIA NSCLC (log‑rank P=0.05, adjusted hazard ratio=2.43, 95% confidence interval=1.04‑5.68, P=0.04). FOSB was identified as a novel gene with tumor‑specific gene body unmethylation in NSCLC and a novel predictive biomarker for NSCLC prognosis. Moreover, the present results indicated that FOSB may have a tumor suppressor function in the progression of NSCLC.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
2	Spiro SG and Silvestri GA: One hundred years of lung cancer. Am J Respir Crit Care Med. 172:523–529. 2005. View Article : Google Scholar : PubMed/NCBI
3	Yano T, Haro A, Shikada Y, Maruyama R and Maehara Y: Non-Small cell lung cancer in never smokers as a representative ‘non-smoking-associated lung cancer’: Epidemiology and clinical features. Int J Clin Oncol. 16:287–293. 2011. View Article : Google Scholar : PubMed/NCBI
4	Bird A: DNA methylation patterns and epigenetic memory. Genes Dev. 16:6–21. 2002. View Article : Google Scholar : PubMed/NCBI
5	Jankowska AM, Millward CL and Caldwell CW: The potential of DNA modifications as biomarkers and therapeutic targets in oncology. Expert Rev Mol Diagn. 15:1325–1337. 2015. View Article : Google Scholar : PubMed/NCBI
6	Lu F and Zhang HT: DNA methylation and nonsmall cell lung cancer. Anat Rec (Hoboken). 294:1787–1795. 2011. View Article : Google Scholar : PubMed/NCBI
7	Seok Y, Lee WK, Park JY and Kim DS: TGFBI promoter methylation is associated with poor prognosis in lung adenocarcinoma patients. Mol Cells. 42:161–165. 2019.PubMed/NCBI
8	Tessema M, Yingling CM, Liu Y, Tellez CS, Van Neste L, Baylin SS and Belinsky SA: Genome-Wide unmasking of epigenetically silenced genes in lung adenocarcinoma from smokers and never smokers. Carcinogenesis. 35:1248–1257. 2014. View Article : Google Scholar : PubMed/NCBI
9	Shaulian E and Karin M: AP-1 as a regulator of cell life and death. Nat Cell Biol. 4:E131–E136. 2002. View Article : Google Scholar : PubMed/NCBI
10	Ting CH, Chen YC, Wu CJ and Chen JY: Targeting FOSB with a cationic antimicrobial peptide, TP4, for treatment of triple-negative breast cancer. Oncotarget. 7:40329–40347. 2016. View Article : Google Scholar : PubMed/NCBI
11	Na HH, Noh HJ, Cheong HM, Kang Y and Kim KC: SETDB1 mediated FosB expression increasing the cell proliferation rate during anticancer drug therapy. BMP Rep. 49:238–243. 2016. View Article : Google Scholar
12	Milde-Langosch K: The fos family of transcription factors and their role in tumorigenesis. Eur J Cancer. 41:2449–2461. 2005. View Article : Google Scholar : PubMed/NCBI
13	Barrett CS, Millena AC and Khan SA: TGF-β effects on prostate cancer cell migration and invasion require FosB. Prostate. 77:72–81. 2017. View Article : Google Scholar : PubMed/NCBI
14	Cervantes-Madrid DL, Nagi S and Asting Gustafsson A: FosB transcription factor regulates COX-2 expression in colorectal cancer cells without affecting PGE2 expression. Oncol Lett. 13:1411–1416. 2017. View Article : Google Scholar : PubMed/NCBI
15	Shahzad MMK, Arevalo JM, Armaiz-Pena GN, Lu C, Stone RL, Moreno-Smith M, Nishimura M, Lee JW, Jennings NB, Bottsford-Miller J, et al: Stress effects on FosB- and interleukin-8 (IL8)-driven ovarian cancer growth and metastasis. J Biol Chem. 285:35462–35470. 2010. View Article : Google Scholar : PubMed/NCBI
16	Renaud SJ, Kubota K, Rumi MA and Soares MJ: The FOS transcription factor family differentially controls trophoblast migration and invasion. J Biol Chem. 289:5025–5039. 2014. View Article : Google Scholar : PubMed/NCBI
17	Rowther FB, Wei W, Dawson TP, Ashton A, Singh A, Madiesse-Timchou MP, Thomas DG, Darling JL and Warr T: Cyclic nucleotide phosphodiesterase-1C (PDE1C) drives cell proliferation, migration and invasion in glioblastoma multiform cells in vitro. Mol Carcinog. 55:268–279. 2016. View Article : Google Scholar : PubMed/NCBI
18	Tang C, Jiang Y, Shao W, Shi W, Gao X, Qin W, Jiang T, Wang F and Feng S: Abnormal expression of FOSB correlates with tumor progression and poor survival in patients with gastric cancer. Int J Oncol. 49:1489–1496. 2016. View Article : Google Scholar : PubMed/NCBI
19	Kim JH, Lee JY, Lee KT, Lee JK, Lee KH, Jang KT, Heo JS, Choi SH and Rhee JC: RGS16 and fosB underexpressed in pancreatic cancer with lymph node metastasis promote tumor progression. Tumour Biol. 31:541–548. 2010. View Article : Google Scholar : PubMed/NCBI
20	Milde-Langosch K, Kappes H, Riethdorf S, Loning T and Bamberger AM: FosB is highly expressed in normal mammary epithelia, but down-regulated in poorly differentiated breast carcinomas. Breast Cancer Res Treat. 77:265–275. 2003. View Article : Google Scholar : PubMed/NCBI
21	Wang LQ, Zhao LH and Qiao YZ: Identification of potential therapeutic targets for lung cancer by bioinformatics analysis. Mol Med Rep. 13:1975–1982. 2016. View Article : Google Scholar : PubMed/NCBI
22	Kim DS, Lee WK and Park JY: Hypermethylation of normal mucosa of esophagus-specific 1 is associated with an unfavorable prognosis in patients with non-small cell lung cancer. Oncol Lett. 16:2409–2415. 2018.PubMed/NCBI
23	Anier K, Malinovskaja K, Aonurm-Helm A, Zharkovsky A and Kalda A: DNA methylation regulates cocaine-induced behavioral sensitization in mice. Neuropsychopharmacol. 35:2450–2461. 2010. View Article : Google Scholar
24	Suzuki T, Yamashita S, Ushijima T, Takumi S, Sano T, Michikawa T and Nohara K: Genome-Wide analysis of DNA methylation changes induced by gestational arsenic exposure in liver tumors. Cancer Sci. 104:1575–1585. 2013. View Article : Google Scholar : PubMed/NCBI
25	Chen ZX and Riggs AD: DNA methylation and demethylation in mammals. J Biol Chem. 286:18347–18353. 2011. View Article : Google Scholar : PubMed/NCBI
26	Kulis M, Heath S, Bibikova M, Queiros AC, Navarro A, Clot G, Martinez-Trillos A, Castellano G, Brun-Health I, Pinyol M, et al: Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. Nat Genet. 44:1236–1242. 2012. View Article : Google Scholar : PubMed/NCBI
27	Yang X, Han H, De Carvalho DD, Lay FD, Jones PA and Liang G: Gene body methylation can alter gene expression and is a therapeutic target in cancer. Cancer Cell. 26:577–590. 2014. View Article : Google Scholar : PubMed/NCBI
28	Kulis M, Queiros AC, Beekman R and Martin-Subero JI: Intragenic DNA methylation in transcriptional regulation, normal differentiation and cancer. Biochim Biophys Acta. 1829:1161–1174. 2013. View Article : Google Scholar : PubMed/NCBI
29	Lee SM, Choi WY, Lee J and Kim YJ: The regulatory mechanisms of intragenic DNA methylation. Epigenomics. 7:527–531. 2015. View Article : Google Scholar : PubMed/NCBI
30	Esteller M: Dormant hypermethylated tumor suppressor genes: Questions and answers. J Pathol. 205:172–180. 2005. View Article : Google Scholar : PubMed/NCBI
31	Milde-Langosch K, Roder H, Andritzky B, Aslan B, Hemminger G, Brinkmann A, Bamberger CM, Loning T and Bamberger AM: The role of the AP-1 transcription factors c-Fos, FosB, Fra-1 and Fra-2 in the invasion process of mammary carcinomas. Breast Cancer Res Treat. 86:139–152. 2004. View Article : Google Scholar : PubMed/NCBI